ZL 1201
Alternative Names: ZL-1201Latest Information Update: 03 Oct 2023
At a glance
- Originator ZAI Lab
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action CD47 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 22 Aug 2023 Drug is still in phase I development in USA (NCT04257617)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Lymphoma(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in USA (IV, Infusion)